Riociguat Treatment for Portopulmonary Hypertension: a Subgroup Analysis from the PATENT-1/-2 Studies

Overview

Journal Pulm Circ

Publisher Wiley

Specialty Pulmonary Medicine

Date 2018 Mar 23

PMID 29565224

Citations 14

Authors

Rodrigo Cartin-Ceba

Michael Halank

Hossein-Ardeschir Ghofrani

Marc Humbert

John Mattson

Arno Fritsch

Michael Krowka

Affiliations

Soon will be listed here.

Abstract

In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.

Citing Articles

Portopulmonary hypertension: Current developments and future perspectives.

Xu H, Cheng B, Wang R, Ding M, Gao Y Liver Res. 2025; 6(1):10-20.

PMID: 39959808 PMC: 11791819. DOI: 10.1016/j.livres.2022.02.002.

Making Living-donor Liver Transplantation a Viable Option for Patients With Portopulmonary Hypertension.

Burton K, Gold A, Abt P, Machado N, Rock K, Bezinover D Transplant Direct. 2024; 10(10):e1710.

PMID: 39328251 PMC: 11427031. DOI: 10.1097/TXD.0000000000001710.

Clinical outcomes of upfront combination therapy for portopulmonary hypertension.

Kiko T, Asano R, Endo H, Nishi N, Hayashi H, Ueda J Int J Cardiol Cardiovasc Risk Prev. 2024; 22:200294.

PMID: 38872733 PMC: 11168483. DOI: 10.1016/j.ijcrp.2024.200294.

Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies.

Kim N, Chin K, McLaughlin V, Dubrock H, Restrepo-Jaramillo R, Safdar Z Pulm Ther. 2024; 10(1):85-107.

PMID: 38184507 PMC: 10881949. DOI: 10.1007/s41030-023-00251-x.

When Pulmonary Arterial Hypertension may be Associated with Portal Hypertension: A Case Report of Two Different Hepatic Disorders in One Patient with Pulmonary Hypertension.

Radchenko G, Sirenko Y Curr Cardiol Rev. 2023; .

PMID: 37881075 PMC: 11071676. DOI: 10.2174/011573403X267162231011154808.

References

Krowka M, Fallon M, Kawut S, Fuhrmann V, Heimbach J, Ramsay M . International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation. 2016; 100(7):1440-52. DOI: 10.1097/TP.0000000000001229. View

Ghofrani H, Galie N, Grimminger F, Grunig E, Humbert M, Jing Z . Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013; 369(4):330-40. DOI: 10.1056/NEJMoa1209655. View

Ghofrani H, Grimminger F, Grunig E, Huang Y, Jansa P, Jing Z . Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med. 2016; 4(5):361-71. DOI: 10.1016/S2213-2600(16)30019-4. View

Galie N, Grimminger F, Grunig E, Hoeper M, Humbert M, Jing Z . Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. J Heart Lung Transplant. 2017; 36(5):509-519. DOI: 10.1016/j.healun.2016.12.012. View

Humbert M, Coghlan J, Ghofrani H, Grimminger F, He J, Riemekasten G . Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis. 2016; 76(2):422-426. PMC: 5284330. DOI: 10.1136/annrheumdis-2015-209087. View

Kahler C, Graziadei I, Vogelsinger H, Desole S, Cima K, Vogel W . Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan. Wien Klin Wochenschr. 2011; 123(7-8):248-52. DOI: 10.1007/s00508-011-1540-4. View

Krowka M, Miller D, Barst R, Taichman D, Dweik R, Badesch D . Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest. 2011; 141(4):906-915. DOI: 10.1378/chest.11-0160. View

Benza R, Miller D, Gomberg-Maitland M, Frantz R, Foreman A, Coffey C . Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122(2):164-72. DOI: 10.1161/CIRCULATIONAHA.109.898122. View

Frey R, Becker C, Unger S, Schmidt A, Wensing G, Muck W . Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulm Circ. 2016; 6(Suppl 1):S5-S14. PMC: 4860536. DOI: 10.1086/685015. View

10.

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Respir J. 2015; 46(4):903-75. DOI: 10.1183/13993003.01032-2015. View

11.

Rosenkranz S, Ghofrani H, Beghetti M, Ivy D, Frey R, Fritsch A . Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart. 2015; 101(22):1792-9. PMC: 4680166. DOI: 10.1136/heartjnl-2015-307832. View

12.

Galie N, Muller K, Scalise A, Grunig E . PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J. 2015; 45(5):1314-22. DOI: 10.1183/09031936.00105914. View

13.

Eriksson C, Gustavsson A, Kronvall T, Tysk C . Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. J Gastrointestin Liver Dis. 2011; 20(1):77-80. View

14.

DuBrock H, Channick R, Krowka M . What's new in the treatment of portopulmonary hypertension?. Expert Rev Gastroenterol Hepatol. 2015; 9(7):983-92. DOI: 10.1586/17474124.2015.1035647. View

15.

Ghofrani H, DArmini A, Grimminger F, Hoeper M, Jansa P, Kim N . Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013; 369(4):319-29. DOI: 10.1056/NEJMoa1209657. View

16.

Stasch J, Evgenov O . Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol. 2013; 218:279-313. DOI: 10.1007/978-3-642-38664-0_12. View

17.

Halank M, Knudsen L, Seyfarth H, Ewert R, Wiedemann B, Kolditz M . Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension. Z Gastroenterol. 2011; 49(9):1258-62. DOI: 10.1055/s-0031-1273393. View